Dawn East

Associate Vice President – Global Medicine Quality
Eli Lilly and Company
 

Dawn East is an Associate Vice President in Global Medicines Quality with organizational leadership responsibilities that provide leadership to the design, maintenance, and implementation of integrated global quality systems that support Research and Development (R&D) activities primarily in the areas of clinical development. She provides direction to the execution of quality systems, management of audit and inspection activities, and appropriate monitoring of the external environment to maintain sustainable compliance and drive continuous improvement.  She leads her teams in setting the strategy, ensuring innovative approaches, and accelerating delivery across the clinical trial portfolio.​  Dawn is known for seamlessly using innovative approaches and analytical insights to drive delivery in creative ways as well as leading teams through complex and ambiguous situations.    

Previously at Lilly, Dawn has held various roles in Clinical, serving as the Associate Vice President leading clinical development across neuroscience as well as leading the COVID antibody development. She served as a  Clinical Research/Development Associate both globally and at the US affiliate supporting neuroscience compounds; as a Clinical Development Liaison supporting clinical trial sites; Pharmaceutical Project Management supporting immunology and neuroscience; as an Information Foundations Advisor working to integrate systems and eliminate duplication of the same data entered into disparate systems; and as a director in Clinical Systems and Supply Planning with a focus on clinical results system including EDC (Libraries, standards, systems, study build and database platforms) and eSource (electronic medical records, eCOA, connect care, apps, digital health, MHealth, etc).  

Prior to coming to Lilly, Dawn was a study coordinator and manager at an independent research center.   She received her undergraduate degree from the University of Evansville in 1998. 

Panel Discussion: Efficiency - Sunrise of Clinical Innovation